Investment Thesis
Lantheus demonstrates exceptional financial health with 61.2% gross margins, 31.4% net margins, and strong free cash flow generation of $79.8M. The company maintains fortress-like liquidity (2.83x current ratio) and conservative leverage (0.47x debt/equity), providing financial flexibility and downside protection. However, near-zero revenue growth (+0.5% YoY) and declining diluted EPS (-21.8% YoY) indicate a mature business model with limited organic expansion, warranting a Buy rating for value/income investors rather than growth investors.
Strengths
- Exceptional profitability: 61.2% gross margin and 31.4% net margin demonstrate strong pricing power and operational efficiency in diagnostic products
- Strong free cash flow: $79.8M FCF with 21.1% FCF margin indicates high-quality earnings conversion and capital generation
- Conservative financial structure: 0.47x debt/equity ratio, 16.7x interest coverage, and $498.6M cash position provide significant financial cushion
- Excellent liquidity: 2.83x current ratio and 2.64x quick ratio indicate robust ability to meet short-term obligations
Risks
- Stagnant revenue growth: +0.5% YoY revenue increase suggests a mature market with limited organic growth catalysts or competitive pressures
- Declining shareholder returns: 21.8% YoY diluted EPS decline despite flat net income indicates share dilution offsetting operational performance
- Moderate capital efficiency: ROE of 9.8% and ROA of 5.0% suggest accumulated capital is not generating exceptional returns
- Sector headwinds: In vitro/in vivo diagnostics face ongoing pricing pressures, reimbursement challenges, and technological disruption
Key Metrics to Watch
- Revenue growth acceleration from current 0.5% baseline to demonstrate market expansion
- Share count trend and EPS accretion/dilution to assess shareholder value creation
- Free cash flow sustainability and capital allocation decisions (buybacks vs. debt reduction vs. R&D investment)
- Gross margin trends as diagnostic pricing environment evolves
Financial Metrics
Revenue
377.3M
Net Income
118.4M
EPS (Diluted)
$1.80
Free Cash Flow
79.8M
Total Assets
2.3B
Cash
498.6M
Profitability Ratios
Gross Margin
61.2%
Operating Margin
21.6%
Net Margin
31.4%
ROE
9.8%
ROA
5.0%
FCF Margin
21.1%
Balance Sheet & Liquidity
Current Ratio
2.83x
Quick Ratio
2.64x
Debt/Equity
0.47x
Debt/Assets
48.3%
Interest Coverage
16.74x
Long-term Debt
569.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:03:40.307875 |
Data as of: 2026-03-31 |
Powered by Claude AI